Pulmonary blood flow (Qp) increased in six cases while it decreased in two. These two cases had a pretreatment Qs less than 3-0 /min per M2. The pulmonary to systemic blood flow ratio (Qp/Qs ratio) decreased only in three patients who had Qs less than 3*0 /min per m2 before hydralazine. In contrast, the Qp/Qs ratio increased in the five cases with higher pretreatment Qs. Thus, this study has found that the pretreatment Qs alters the effect of hydralazine on the Qp/Qs ratio in large ventricular septal defects, thus indicating that afterload reduction treatment with hydralazine may be effective in the management of large ventricular septal defects by reducing the Qp/Qs ratio in the cases that are associated with a low systemic blood flow.
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Vasodilators are effective in the management of compromised cardiac performance which is secondary to various heart diseases such as primary or ischaemic congestive cardiomyopathy, and mitral and/or aortic regurgitation.'-6 It has been suggested that a reduction of systemic vascular resistance in large ventricular septal defects results in an increase of the flow through the aortic outflow tract, while the flow through the septal defect decreases or stays constant, which leads to a decrease in the pulmonary to systemic flow ratio (Qp/Qs ratio). This has been supported by animal experiment7 and clinical study.8 The subjects studied in those reports, however, do not necessarily represent the haemodynamic condition which we often observe in infants with a large ventricular septal defect. This study was therefore undertaken to evaluate the effects of afterload reducAccepted for publication 3 February 1983 tion treatment in infants and younger children with a large ventricular septal defect who have been admitted to hospital for surgical treatment.
Subjects and methods
Eight patients with an isolated ventricular septal defect were the subjects of this study. The clinical and basic haemodynamic data are summarised in Table 1. Seven cases were under 12 months of age. One case older than this was included because of an important observation, which will be discussed later. This case had tachypnoea, small peripheral pulses, pronounced perspiration, and pale skin. All the patients were admitted to hospital for surgical treatment because they had had frequent respiratory tract infections, pulmonary hypertension, or had failed to thrive. Informed consent was obtained for this study. All patients received pethidine-HCl, 1 mg/kg, and hyd- 30- less before hydralazine, and the reduction was associated with a decrease or minimal increase in the Qp. On the other hand, the Qp/Qs ratio increased in the five patients who had the higher Qs and this was associated with a significant increase in Qp (Fig. 4 , Table 2 ). It is known that the volume of left to right shunt is determined by aortic impedance to left ventricular ejection in ventricular septal defect.7 10 1 1 An increase in systemic vascular resistance results in an increase in the shunt, and vice versa. This will be the case when the septal defect is restrictive, or when pulmonary vascular resistance does not respond to intervention. In a large and non-restrictive ventricular septal defect, the Qp/Qs ratio is determined by the relative resistance of systemic and pulmonary vascular beds. '2 This indicates that the effect of vasodilators on the Qp/Qs ratio is dependent upon the relative responsiveness of systemic and pulmonary circulation to the drug. As shown in this study, pulmonary vascular resistance is usually higher than normal in infants with a large ventricular septal defect. In this condition, when associated with no systemic vasoconstriction, the effect of hydralazine would be more pronounced on the pulmonary circulation than on the systemic, thus resulting in an increase of the Qp/Qs ratio. This is the same response as reported by Macri and Redaelli'3 and Linday et al. '4 It is, therefore, suspected that their subjects had the same haemodynamic characteristics as we have just described.
A large ventricular septal defect is occasionally associated with low systemic blood flow and with high systemic vascular resistance which will be manifested by clinical findings such as tachycardia, small peripheral pulse, pronounced perspiration, and a cold and pale skin. In these cases, the Qp/Qs ratio would' be largely influenced by systemic vascular The other significant effect observed in this study was a lowering of the left atrial pressure. The fact that high left atrial pressure is often associated with tachypnoea and/or retention of carbon dioxide in patients with a large ventricular septal defect indicates that interstitial oedema of alveoli caused by an increase of pulmonary venous pressure may play a role in the respiratory problems. Thus lowering left atrial pressure should theoretically improve the gas exchange. Further clinical observation is needed to confirm this effect.
In summary, hydralazine reduced the Qp/Qs ratio only in cases with low systemic blood flow, thus implying that it may be beneficial in those cases. This agent, however, increased the Qp/Qs ratio and Qp in cases which had had normal or high systemic blood flow before hydralazine. Thus, the study has shown that the effect of hydralazine is dependent upon the pretreatment haemodynamic state. 
